Skip to main content
SpringerLink
Log in

RETRACTED ARTICLE: Relationships between PON1 Q192R polymorphism and clinical outcome of antiplatelet treatment after percutaneous coronary intervention: a meta-analysis

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

This article was retracted on 18 August 2015

Abstract

This meta-analysis was performed to assess the relationships between the PON1 Q192R (rs662 T>C) polymorphism and the clinical outcome of antiplatelet treatment after percutaneous coronary intervention (PCI). A range of electronic databases were searched: Web of Science (1945–2013), the Cochrane Library Database (Issue 12, 2013), PubMed (1966–2013), EMBASE (1980–2013), CINAHL (1982–2013) and the Chinese Biomedical Database (CBM) (1982–2013) without language restrictions. Meta-analysis was conducted using the STATA 12.0 software. The crude odds ratio (OR) with their 95 % confidence interval (CI) were calculated. Six clinical cohort studies with a total number of 5,189 patients undergoing PCI for coronary heart disease were included. Our meta-analysis revealed that the PON1 Q192R polymorphism was correlated with an increased risk of major adverse cardiovascular events (MACE) in patients receiving antiplatelet treatment after PCI (C allele vs. T allele: OR = 1.22, 95 % CI 1.04–1.43, P = 0.014; CT+CC vs. TT: OR = 1.38, 95 % CI 1.03–1.86, P = 0.029; CC vs. TT: OR = 1.45, 95 % CI 1.05–1.99, P = 0.024; respectively), especially among Asians. Furthermore, we found significantly positive correlations between the PON1 Q192R polymorphism and the incidence of stent thrombosis in patients receiving antiplatelet treatment after PCI (C allele vs. T allele: OR = 1.42, 95 % CI 1.08–1.87, P = 0.011; CT+CC vs. TT: OR = 1.93, 95 % CI 1.01–3.67, P = 0.046; CC vs. TT: OR = 2.18, 95 % CI 1.09–4.35, P = 0.027; respectively). Our meta-analysis of clinical cohort studies provides evidence that the PON1 Q192R polymorphism may increase the risk of MACE and stent thrombosis in patients receiving antiplatelet treatment after PCI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Caggegi A, Capodanno D, Capranzano P, Chisari A, Ministeri M, Mangiameli A, Ronsivalle G, Ricca G et al (2011) Comparison of one-year outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in patients with unprotected left main coronary artery disease and acute coronary syndromes (from the customize registry). Am J Cardiol 108:355–359. doi:10.1016/j.amjcard.2011.03.050

    Article  PubMed  Google Scholar 

  2. Mause SF, Ritzel E, Liehn EA, Hristov M, Bidzhekov K, Muller-Newen G, Soehnlein O, Weber C (2010) Platelet microparticles enhance the vasoregenerative potential of angiogenic early outgrowth cells after vascular injury. Circulation 122:495–506. doi:10.1161/CIRCULATIONAHA.109.909473

    Article  PubMed  Google Scholar 

  3. Lhermusier T, Van Rothem J, Garcia C, Gratacap MP, Payrastre B (2011) Targeted drug therapy: the platelet side. Platelets 22:479–484. doi:10.3109/09537104.2011.567423

    Article  CAS  PubMed  Google Scholar 

  4. Chhatriwalla AK, Bhatt DL (2008) Should dual antiplatelet therapy after drug-eluting stents be continued for more than one-year? Dual antiplatelet therapy after drug-eluting stents should be continued for more than one-year and preferably indefinitely. Circ Cardiovasc Interv 1:217–225. doi:10.1161/CIRCINTERVENTIONS.108.811380

    Article  PubMed  Google Scholar 

  5. Tousoulis D, Paroutoglou IP, Papageorgiou N, Charakida M, Stefanadis C (2010) Recent therapeutic approaches to platelet activation in coronary artery disease. Pharmacol Ther 127:108–120. doi:10.1016/j.pharmthera.2010.05.001

    Article  CAS  PubMed  Google Scholar 

  6. Park KW, Park JJ, Kang J, Jeon KH, Kang SH, Han JK, Lee SE, Yang HM et al (2013) Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI. PLoS One 8:e52779. doi:10.1371/journal.pone.0052779

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Trenk D, Hochholzer W, Fromm MF, Zolk O, Valina CM, Stratz C, Neumann FJ (2011) Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 4:429–436. doi:10.1161/CIRCGENETICS.111.960112

    Article  CAS  PubMed  Google Scholar 

  8. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, Furlong CE (2000) Catalytic efficiency determines the in vivo efficacy of pon1 for detoxifying organophosphorus compounds. Pharmacogenetics 10:767–779

    Article  CAS  PubMed  Google Scholar 

  9. Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, Scott SA, Montalescot G (2011) CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 4:422–428. doi:10.1161/CIRCINTERVENTIONS.111.963025

    Article  CAS  PubMed  Google Scholar 

  10. Wang X, Fan Z, Huang J, Su S, Yu Q, Zhao J, Hui R, Yao Z et al (2003) Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol 23:328–334. doi:10.1161/01.ATV.0000051702.38086.C1

    Article  CAS  PubMed  Google Scholar 

  11. Bouman HJ, Schomig E, van Werkum JW, Velder J, Hackeng CM, Hirschhauser C, Waldmann C, Schmalz HG et al (2011) Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 17:110–116. doi:10.1038/nm.2281

    Article  CAS  PubMed  Google Scholar 

  12. Lewis JP, Fisch AS, Ryan K, O’Connell JR, Gibson Q, Mitchell BD, Shen H, Tanner K et al (2011) Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin Pharmacol Ther 90:568–574. doi:10.1038/clpt.2011.194

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Plosker GL, Lyseng-Williamson KA (2007) Clopidogrel: a review of its use in the prevention of thrombosis. Drugs 67:613–646

    Article  CAS  PubMed  Google Scholar 

  14. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM et al (2002) Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 30:1288–1295. doi:10.1124/dmd.30.11.1288

    Article  CAS  PubMed  Google Scholar 

  15. Camps J, Joven J, Mackness B, Mackness M, Tawfik D, Draganov D, Costa LG, Paragh G et al (2011) Paraoxonase-1 and clopidogrel efficacy. Nat Med 17:1041–1042. doi:10.1038/nm.2386

    Article  CAS  PubMed  Google Scholar 

  16. Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, Schork NJ, Teirstein PS et al (2012) Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the gift (genotype information and functional testing) study. J Am Coll Cardiol 59:1928–1937. doi:10.1016/j.jacc.2011.11.068

    Article  CAS  PubMed  Google Scholar 

  17. Chen DY, Wang CY, Wen MS, Lee TH, Chu Y, Hsieh MJ, Chang SH, Lee CH et al (2012) Paraoxonase-1 is not a major determinant of stent thrombosis in a taiwanese population. PLoS One 7:e39178. doi:10.1371/journal.pone.0039178

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Stang A (2010) Critical evaluation of the Newcastle–Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605. doi:10.1007/s10654-010-9491-z

    Article  PubMed  Google Scholar 

  19. Zintzaras E, Ioannidis JP (2005) Hegesma: genome search meta-analysis and heterogeneity testing. Bioinformatics 21:3672–3673. doi:10.1093/bioinformatics/bti536

    Article  CAS  PubMed  Google Scholar 

  20. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2006) Comparison of two methods to detect publication bias in meta-analysis. JAMA 295:676–680. doi:10.1001/jama.295.6.676

    Article  CAS  PubMed  Google Scholar 

  21. Campo G, Ferraresi P, Marchesini J, Bernardi F, Valgimigli M (2011) Relationship between paraoxonase q192r gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention. J Thromb Haemost 9:2106–2108. doi:10.1111/j.1538-7836.2011.04457.x

    Article  CAS  PubMed  Google Scholar 

  22. Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I et al (2011) No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 32:1605–1613. doi:10.1093/eurheartj/ehr155

    Article  CAS  PubMed  Google Scholar 

  23. Tang XF, Wang J, Zhang JH, Meng XM, Xu B, Qiao SB, Wu YJ, Chen J et al (2013) Effect of the CYP2C19 2 and 3 genotypes, abcb1 C3435T and pon1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol 69:1103–1112. doi:10.1007/s00228-012-1446-8

    Article  CAS  PubMed  Google Scholar 

  24. Verschuren JJ, Boden H, Wessels JA, van der Hoeven BL, Trompet S, Heijmans BT, Putter H, Guchelaar HJ et al (2013) Value of platelet pharmacogenetics in common clinical practice of patients with st-segment elevation myocardial infarction. Int J Cardiol 167:2882–2888. doi:10.1016/j.ijcard.2012.07.020

    Article  PubMed  Google Scholar 

  25. Getz GS, Reardon CA (2004) Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol 15:261–267

    Article  CAS  PubMed  Google Scholar 

  26. Costa LG, Cole TB, Vitalone A, Furlong CE (2005) Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta 352:37–47. doi:10.1016/j.cccn.2004.09.019

    Article  CAS  PubMed  Google Scholar 

  27. Simon T, Steg PG, Becquemont L, Verstuyft C, Kotti S, Schiele F, Ferrari E, Drouet E et al (2011) Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin Pharmacol Ther 90:561–567. doi:10.1038/clpt.2011.193

    Article  CAS  PubMed  Google Scholar 

  28. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411–2420. doi:10.1001/jama.288.19.2411

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to acknowledge the reviewers for their helpful comments on this paper. This work was supported by Natural Science Foundation of China (NSFC) (grant #81202598), Shanghai Municipal Public Health Bureau (grant #2009068).

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pharmacy, The Affiliated Xinhua Hospital of Shanghai Jiaotong University, Kongjiang Road No. 1665, Yangpu District, Shanghai, 200082, People’s Republic China

    Ping Li, Shu-Hong Bu, Xiao-Tong Lu, Li-Xia Li, A-Jing Xu, Yue-Nian Tang & Jian Zhang

Authors
  1. Ping Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shu-Hong Bu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiao-Tong Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Li-Xia Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A-Jing Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yue-Nian Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian Zhang.

Additional information

The Publisher and Editor retract this article in accordance with the recommendations of the Committee on Publication Ethics (COPE). After a thorough investigation we have strong reason to believe that the peer review process was compromised.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, P., Bu, SH., Lu, XT. et al. RETRACTED ARTICLE: Relationships between PON1 Q192R polymorphism and clinical outcome of antiplatelet treatment after percutaneous coronary intervention: a meta-analysis. Mol Biol Rep 41, 6263–6273 (2014). https://doi.org/10.1007/s11033-014-3509-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-014-3509-7

Keywords

Search

Navigation